Drug Shortage Report for MYCAMINE
| Report ID | 250175 |
| Drug Identification Number | 02294222 |
| Brand name | MYCAMINE |
| Common or Proper name | Mycamine |
| Company Name | ASTELLAS PHARMA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | MICAFUNGIN SODIUM |
| Strength(s) | 50MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 10mL Vial Pk |
| ATC code | J02AX |
| ATC description | ANTIMYCOTICS FOR SYSTEMIC USE |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2025-02-11 |
| Actual start date | 2025-02-11 |
| Estimated end date | Unknown |
| Actual end date | 2025-03-20 |
| Shortage status | Resolved |
| Updated date | 2025-04-08 |
| Company comments | Market Authorization Transfer (MAT) of Mycamine to Sandoz Canada occurred on March 20, 2025 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 675 COCHRANE DRIVE, WEST TOWER, SUITE 650 MARKHAM, ONTARIO CANADA L3R 0B8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2025-04-08 | French | Compare |
| v4 | 2025-04-08 | English | Compare |
| v3 | 2025-02-12 | English | Compare |
| v2 | 2025-02-11 | French | Compare |
| v1 | 2025-02-11 | English | Compare |
Showing 1 to 5 of 5